Jaap Fransen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8436734/publications.pdf

Version: 2024-02-01

		218677	155660
55	4,001 citations	26	55
papers	citations	h-index	g-index
56	56	56	5368
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.9	794
2	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1789-1798.	0.9	545
3	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2557-2568.	5.6	393
4	The Disease Activity Score and the EULAR Response Criteria. Rheumatic Disease Clinics of North America, 2009, 35, 745-757.	1.9	380
5	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 2087-2093.	0.9	168
6	Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 1868-1874.	0.9	145
7	Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosis. Arthritis and Rheumatology, 2016, 68, 462-472.	5.6	131
8	The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2015, 74, 998-1003.	0.9	121
9	Persistent severe fatigue in patients with rheumatoid arthritis. Journal of Clinical Nursing, 2007, 16, 377-383.	3.0	113
10	Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout. Arthritis Care and Research, 2015, 67, 1304-1315.	3.4	101
11	Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. Arthritis and Rheumatology, 2017, 69, 429-438.	5.6	93
12	Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and Response. Journal of Rheumatology, 2014, 41, 1212-1217.	2.0	85
13	Is fatigue a disease-specific or generic symptom in chronic medical conditions?. Health Psychology, 2018, 37, 530-543.	1.6	79
14	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	5.0	52
15	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
16	The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. Rheumatology, 2015, 54, 609-614.	1.9	47
17	Outcome measures in inflammatory rheumatic diseases. Arthritis Research and Therapy, 2009, 11 , 244.	3.5	44
18	Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis. RMD Open, 2016, 2, e000202.	3.8	43

#	Article	IF	CITATIONS
19	Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Annals of the Rheumatic Diseases, 2017, 76, 1716-1722.	0.9	39
20	Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clinical Rheumatology, 2019, 38, 1385-1391.	2.2	39
21	Performance of classification criteria for gout in early and established disease. Annals of the Rheumatic Diseases, 2016, 75, 178-182.	0.9	36
22	Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis Care and Research, 2016, 68, 1894-1898.	3.4	34
23	Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology, 2016, 55, 2001-2008.	1.9	34
24	Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics, 2012, 13, 1087-1094.	1.3	33
25	Crystal-proven Gout and Characteristic Gout Severity Factors Are Associated with Cardiovascular Disease. Journal of Rheumatology, 2018, 45, 858-863.	2.0	33
26	The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus. PLoS ONE, 2015, 10, e0132307.	2.5	31
27	Efficacy of a Web-Based Self-Management Enhancing Program for Patients with Rheumatoid Arthritis: Explorative Randomized Controlled Trial. Journal of Medical Internet Research, 2019, 21, e12463.	4.3	27
28	Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. Journal of Rheumatology, 2016, 43, 150-153.	2.0	25
29	Arthritis of the first metatarsophalangeal joint is not always gout: A prospective cohort study in primary care patients. Joint Bone Spine, 2014, 81, 342-346.	1.6	21
30	Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. Journal of Rheumatology, 2016, 43, 1838-1843.	2.0	21
31	Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study. Journal of Rheumatology, 2017, 44, 1325-1330.	2.0	21
32	The effect of curriculum sample selection for medical school. Advances in Health Sciences Education, 2017, 22, 43-56.	3.3	20
33	IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis. Scientific Reports, 2017, 7, 41629.	3.3	20
34	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials, 2017, 18, 403.	1.6	18
35	Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare. RMD Open, 2015, 1, e000114.	3.8	14
36	Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. Trials, 2018, 19, 449.	1.6	14

#	Article	IF	Citations
37	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. Pharmacogenomics, 2019, 20, 85-93.	1.3	13
38	A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 200-6.	0.8	13
39	Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population presenting with monoarthritis. Rheumatology, 2017, 56, 1335-1341.	1.9	12
40	Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model. Journal of Rheumatology, 2015, 42, 398-404.	2.0	11
41	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. Rheumatology, 2016, 55, 2023-2032.	1.9	9
42	Desirability Scores for Assessing Multiple Outcomes in Systemic Rheumatic Diseases. Communications in Statistics - Theory and Methods, 2009, 38, 3461-3471.	1.0	8
43	Costâ€Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2017, 69, 175-182.	3.4	8
44	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis. Journal of Scleroderma and Related Disorders, 2020, 5, 57-65.	1.7	8
45	Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study. Arthritis Research and Therapy, 2021, 23, 2.	3.5	8
46	Serum Samples That Have Been Stored Long-Term (>10 Years) Can Be Used as a Suitable Data Source for Developing Cardiovascular Risk Prediction Models in Large Observational Rheumatoid Arthritis Cohorts. BioMed Research International, 2014, 2014, 1-8.	1.9	7
47	Validity of the disease activity score in undifferentiated arthritis. Arthritis Care and Research, 2010, 62, 1392-1398.	3.4	6
48	Determinants Associated with Work Participation in Patients with Established Rheumatoid Arthritis Taking Tumor Necrosis Factor Inhibitors. Journal of Rheumatology, 2014, 41, 1263-1269.	2.0	6
49	A Simplified Baseline Prediction Model for Joint Damage Progression in Rheumatoid Arthritis: A Step toward Personalized Medicine. Journal of Rheumatology, 2015, 42, 391-397.	2.0	6
50	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. Journal of Rheumatology, 2021, 48, jrheum.201594.	2.0	6
51	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. BMJ Open, 2016, 6, e012026.	1.9	5
52	Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study: reply. Rheumatology, 2015, 54, 1329-1330.	1.9	4
53	What Should Be the Cut Point for Classification Criteria of Studies in Gout? A Conjoint Analysis. Arthritis Care and Research, 2016, 68, 1731-1735.	3.4	4
54	Specificity of Systemic Sclerosis Classification Criteria. Journal of Rheumatology, 2015, 42, 2512-2512.	2.0	3

#	Article	IF	CITATIONS
55	(Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 767-8.	0.8	1